Reducing the risk of chronic hypertension and improving vascular function following preeclampsia
Project Number1R01HD112930-01A1
Former Number1R01HD112930-01
Contact PI/Project LeaderPALATNIK, ANNA
Awardee OrganizationMEDICAL COLLEGE OF WISCONSIN
Description
Abstract Text
Project Abstract/Summary
Hypertensive disorder of pregnancy (HDP) is a major public health problem especially postpartum. Postpartum
hypertension (HTN) accounts for nearly 75% of maternal hemorrhagic strokes, heart failures, and deaths, one-
third of which occurs in the first week after birth. Patients who survive these devastating complications face a
lifelong sequela of cardiovascular disease (CVD). The mechanisms behind the increased risk of CVD involve
vascular dysfunction generated by HDP and further exacerbated by postpartum HTN. The postpartum period is
a time of high vascular remodeling following pregnancy, and even more so following a hypertensive pregnancy.
Patients who had HDP have lower flow mediated dilation (FMD) and higher arterial stiffness measured by pulse
wave velocity (PWV) compared to patients with no HDP. They also have higher levels of soluble fms-like tyrosine
kinase-1 (sFlt-1), an anti-angiogenic protein that causes vasoconstriction and endothelial damage. Our
preliminary studies demonstrate that intensive blood pressure (BP) control to target of <140/90 mmHg for 6
weeks after giving birth is safe and leads to lower rates of immediate postpartum complications. However, two
critical gaps in knowledge remain: 1) Does more intensive postpartum therapy during vascular remodeling
reduce the number of individuals with chronic HTN at one-year postpartum, and 2) Does the favorable impact of
lowering BP translate into improved vascular function and biomarkers of cardiovascular risk, known to predict
future adverse CV events. We plan to address these gaps with Reducing the risk of chronic hypErtension and
imProving vAscular functIon following pReeclampsia (REPAIR) study, a multicenter randomized controlled trial
of 618 patients with HDP randomized to tight BP control postpartum versus usual care. Our central hypothesis
is that intensive short-term (for 6 weeks) BP control during vascular remodeling that happens after childbirth, will
accelerate recovery of vascular function and reduce the risk of chronic HTN and future CVD. We will pursue the
following two specific aims: 1) Determine the effect of intensive postpartum BP control on new diagnosis of
chronic HTN at one year postpartum; and 2) Determine the effect of intensive postpartum BP control on vascular
function and biomarkers of cardiovascular risk following HDP. We will utilize remote BP monitoring with daily
medication adjustment the first 6 weeks postpartum, the time when there are substantial fluctuations in BP. Given
racial disparities in HDP and CVD, oversampling of Black patients with HDP will be done to ensure they comprise
50% of study participants. The primary outcome, new onset chronic HTN, defined as stage I HTN ≥130/80
mmHg, and secondary outcomes, change in FMD, PWV, and sFlt-1, will be evaluated at one year postpartum.
The REPAIR study will provide high-level evidence for BP management postpartum and will have a direct impact
on clinical practice. If proven effective, the REPAIR study will lead to standardization of postpartum BP
management and to reduction in the long-term risk of CVD following HDP. This contribution will be significant
because the at-risk population for HDP is growing and our impact will increase over time.
Public Health Relevance Statement
PROJECT NARRATIVE
The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on
maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by
hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2 arm randomized control trialAccelerationAddressAffectAngiogenesis InhibitorsAngiogenic ProteinsBiological MarkersBirthBloodBlood PressureBlood Pressure MonitorsBlood VesselsBrain hemorrhageCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCessation of lifeChildbirthChronicDiagnosisEndotheliumEnsureEventFaceFemurFutureGoalsHeart failureHypertensionIndividualKnowledgeLevel of EvidenceMeasuresMediatingNewly DiagnosedNifedipineNot Hispanic or LatinoParticipantPatientsPerinatalPharmaceutical PreparationsPhysiologic pulsePopulations at RiskPostpartum HypertensionPostpartum PeriodPre-EclampsiaPregnancyProtocols documentationPublic HealthRandomizedRandomized, Controlled TrialsRecoveryRiskRisk ReductionSamplingSerumSiteStandardizationTestingTimeTranslatingVascular DiseasesVascular Endothelial Growth Factor Receptor-1Vascular remodelingWorkactive control grouparterial stiffnessblack patientblood pressure controlbrachial arterycardiovascular disorder riskcardiovascular healthcardiovascular risk factorclinical practicecomparison controlendothelial dysfunctiongroup interventionhypertensiveimprovedinnovationnovelpost pregnancypostpartum complicationspregnancy disorderpregnancy hypertensionprimary outcomeracial disparityresponsesecondary outcometelemonitoringtreatment as usualvascular inflammationvascular injuryvasoconstriction
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
937639060
UEI
E8VWJXMMUQ67
Project Start Date
03-July-2024
Project End Date
30-June-2029
Budget Start Date
03-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$632,110
Direct Costs
$500,126
Indirect Costs
$131,984
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$632,110
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01HD112930-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HD112930-01A1
Patents
No Patents information available for 1R01HD112930-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HD112930-01A1
Clinical Studies
No Clinical Studies information available for 1R01HD112930-01A1
News and More
Related News Releases
No news release information available for 1R01HD112930-01A1
History
No Historical information available for 1R01HD112930-01A1
Similar Projects
No Similar Projects information available for 1R01HD112930-01A1